Zepteon
Maria Grunwald is a seasoned business development professional in the life sciences sector, currently serving as Chief Business Officer (CBO) at Inipharm, Inc. and Biopharmaceutical Research Company, and as Senior Business Advisor at Altamira Therapeutics and FarmaMondo SA. With a robust background in strategic partnerships and licensing, Grunwald has held leadership roles in various organizations, including Zepteon, Inc. and novAIZen, while also advising on business strategies since 2012. Academic credentials encompass a Ph.D. in Neuroscience from Johns Hopkins University and an MBA from the MIT Sloan School of Management, complemented by foundational degrees in Biochemistry.
This person is not in any teams
Zepteon
Zepteon, Inc. is a privately held corporation founded in 2012 that has developed first in class chromatography resins capable of separating antibodies with specific sugar structures (nonfucosylated) that are more potent against diseases like cancer. This technology enables more effective therapeutics and can reduce cost and dosing requirements.